E J Edelman1,2, K S Gordon3, J P Tate4,3, W C Becker4,3, K Bryant5, K Crothers6, J R Gaither4,3,7, C L Gibert8, A J Gordon9, Bdl Marshall10, M C Rodriguez-Barradas11, J H Samet12, M Skanderson3, A C Justice4,13,3, D A Fiellin4,13. 1. Yale University School of Medicine, New Haven, CT, USA. ejennifer.edelman@yale.edu. 2. Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT, USA. ejennifer.edelman@yale.edu. 3. VA Connecticut Health Care System, West Haven, CT, USA. 4. Yale University School of Medicine, New Haven, CT, USA. 5. National Institute on Alcohol Abuse and Alcoholism, HIV/AIDS Program, Bethesda, MD, USA. 6. University of Washington, Seattle, WA, USA. 7. Yale University School of Public Health, New Haven, CT, USA. 8. DC Veterans Affairs Medical Center and George Washington University, Washington, DC, USA. 9. Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, Pittsburgh, PA, USA. 10. Brown University School of Public Health, Providence, RI, USA. 11. Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA. 12. Boston University Schools of Medicine and Public Health, Boston, MA, USA. 13. Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT, USA.
Abstract
OBJECTIVES: Certain prescribed opioids have immunosuppressive properties, yet their impact on clinically relevant outcomes, including antiretroviral therapy (ART) response among HIV-infected patients, remains understudied. METHODS: Using the Veterans Aging Cohort Study data, we conducted a longitudinal analysis of 4358 HIV-infected patients initiating ART between 2002 and 2010 and then followed them for 24 months. The primary independent variable was prescribed opioid duration, categorized using pharmacy data as none prescribed, short-term (< 90 days) and long-term (≥ 90 days). Outcomes included CD4 cell count over time. Analyses adjusted for demographics, comorbid conditions, ART type and year of initiation, and overall disease severity [ascertained with the Veterans Aging Cohort Study (VACS) Index]. Sensitivity analyses examined whether effects varied according to baseline CD4 cell count, achievement of viral load suppression, and opioid properties (i.e. dose and known immunosuppressive properties). RESULTS: Compared to those with none, patients with short-term opioids had a similar increase in CD4 cell count (mean rise per year: 74 vs. 68 cells/μL; P = 0.11), as did those with long-term prescribed opioids (mean rise per year: 74 vs. 75 cells/μL; P = 0.98). In sensitivity analysis, compared with no opioids, the effects of short-term prescribed opioids were statistically significant among those with a baseline CD4 cell count ≥ 500 cells/μL (mean rise per year: 52 cells/μL for no opioids vs. 20 cells/μL for short-term opioids; P = 0.04); findings were otherwise unchanged. CONCLUSIONS: Despite immunosuppressive properties intrinsic to opioids, prescribed opioids appeared to have no effect on CD4 cell counts over 24 months among HIV-infected patients initiating ART.
OBJECTIVES: Certain prescribed opioids have immunosuppressive properties, yet their impact on clinically relevant outcomes, including antiretroviral therapy (ART) response among HIV-infectedpatients, remains understudied. METHODS: Using the Veterans Aging Cohort Study data, we conducted a longitudinal analysis of 4358 HIV-infectedpatients initiating ART between 2002 and 2010 and then followed them for 24 months. The primary independent variable was prescribed opioid duration, categorized using pharmacy data as none prescribed, short-term (< 90 days) and long-term (≥ 90 days). Outcomes included CD4 cell count over time. Analyses adjusted for demographics, comorbid conditions, ART type and year of initiation, and overall disease severity [ascertained with the Veterans Aging Cohort Study (VACS) Index]. Sensitivity analyses examined whether effects varied according to baseline CD4 cell count, achievement of viral load suppression, and opioid properties (i.e. dose and known immunosuppressive properties). RESULTS: Compared to those with none, patients with short-term opioids had a similar increase in CD4 cell count (mean rise per year: 74 vs. 68 cells/μL; P = 0.11), as did those with long-term prescribed opioids (mean rise per year: 74 vs. 75 cells/μL; P = 0.98). In sensitivity analysis, compared with no opioids, the effects of short-term prescribed opioids were statistically significant among those with a baseline CD4 cell count ≥ 500 cells/μL (mean rise per year: 52 cells/μL for no opioids vs. 20 cells/μL for short-term opioids; P = 0.04); findings were otherwise unchanged. CONCLUSIONS: Despite immunosuppressive properties intrinsic to opioids, prescribed opioids appeared to have no effect on CD4 cell counts over 24 months among HIV-infectedpatients initiating ART.
Authors: Bradley C Martin; Ming-Yu Fan; Mark J Edlund; Andrea Devries; Jennifer Brennan Braden; Mark D Sullivan Journal: J Gen Intern Med Date: 2011-07-13 Impact factor: 5.128
Authors: Neel R Gandhi; Janet P Tate; Maria C Rodriguez-Barradas; David Rimland; Matthew Bidwell Goetz; Cynthia Gibert; Sheldon T Brown; Kristin Mattocks; Amy C Justice Journal: Pharmacoepidemiol Drug Saf Date: 2013-07-09 Impact factor: 2.890
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Amy C Justice; Elizabeth Dombrowski; Joseph Conigliaro; Shawn L Fultz; Deborah Gibson; Tamra Madenwald; Joseph Goulet; Michael Simberkoff; Adeel A Butt; David Rimland; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Sheldon Brown; David A Leaf; Matthew B Goetz; Kendall Bryant Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner Journal: Clin J Pain Date: 2008 Jul-Aug Impact factor: 3.442
Authors: Joseph Cofrancesco; Rebecca Scherzer; Phyllis C Tien; Cynthia L Gibert; Heather Southwell; Stephen Sidney; Adrian Dobs; Carl Grunfeld Journal: AIDS Date: 2008-01-30 Impact factor: 4.177
Authors: Robert M Donahoe; Shawn P O'neil; Frederick A Marsteller; Francis J Novembre; Daniel C Anderson; Pamela Lankford-Turner; Harold H McClure Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: E Jennifer Edelman; Kirsha S Gordon; Kristina Crothers; Kathleen Akgün; Kendall J Bryant; William C Becker; Julie R Gaither; Cynthia L Gibert; Adam J Gordon; Brandon D L Marshall; Maria C Rodriguez-Barradas; Jeffrey H Samet; Amy C Justice; Janet P Tate; David A Fiellin Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873
Authors: Jessica S Merlin; Dustin Long; William C Becker; Edward R Cachay; Katerina A Christopoulos; Kasey Claborn; Heidi M Crane; E Jennifer Edelman; Richard Harding; Stefan G Kertesz; Jane M Liebschutz; W Christopher Mathews; Michael J Mugavero; Sonia Napravnik; Connall C OʼCleirigh; Michael S Saag; Joanna L Starrels; Robert Gross Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Joëlla W Adams; Yu Li; Declan T Barry; Kirsha S Gordon; Robert D Kerns; Benjamin J Oldfield; Christopher T Rentsch; Brandon D L Marshall; E Jennifer Edelman Journal: AIDS Behav Date: 2021-02-10
Authors: GYeon Oh; Emily S Brouwer; Erin L Abner; David W Fardo; Patricia R Freeman; Chris Delcher; Daniela C Moga Journal: Sci Rep Date: 2021-07-29 Impact factor: 4.379